European Archives of Oto-Rhino-Laryngology

, Volume 266, Issue 8, pp 1291–1300 | Cite as

Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)

  • Andreas DietzEmail author
  • Volker Rudat
  • Jens Dreyhaupt
  • Maria Pritsch
  • Florian Hoppe
  • Rudolph Hagen
  • Leo Pfreundner
  • Ursula Schröder
  • Hans Eckel
  • Markus Hess
  • Michael Schröder
  • Petra Schneider
  • Bünzel Jens
  • Hans P. Zenner
  • Jochen A. Werner
  • Rita Engenhardt-Cabillic
  • Bernhard Vanselow
  • Peter Plinkert
  • Marcus Niewald
  • Thomas Kuhnt
  • Wilfried Budach
  • Michael Flentje
Head and Neck


A prospective multicenter phase-II trial (12 centers) was performed by the German larynx organ preservation group (DeLOS) to evaluate the effect of induction chemotherapy (ICHT) with paclitaxel/cisplatin (TP), followed by accelerated-hyperfractionated (concomitant boost) radiotherapy (RT) in responders. The trial was focused on larynx preservation, tumor control, survival, salvage surgery and late toxicity in patients with advanced larynx/hypopharynx carcinoma eligible for total laryngectomy (LE). Seventy-one patients (40 larynx, 87.5% St. III, IV; 31 hypopharynx, 93.4% St. III, IV) were enrolled into the study and treated with ICHT (200 mg/m2 paclitaxel, 100 mg/m2 cisplatin; day 1, 22) according to the DeLOS protocol. Patients with complete or partial tumor response proceeded to RT (69.9 Gy in 5.5 weeks). Non-responders received a LE followed by postoperative RT (56–70 Gy in 5.5–7 weeks). The response rate to ICHT for larynx cancer was 69.6% (7.1% complete, 62.5% partial response) and for hypopharyngeal cancer was 84.3% (6.9% complete, 77.4% partial response). Overall survival after 36 months was 60.3% (95% CI, 48.4–72.2%), after 42 months was 56.5% (95% CI, 44.2–68.8%). Laryngectomy-free survival was as follows: after 36 months, 43.0% (95% CI, 30.9–55.0%); after 42 months, 41.3% (95% CI, 29.3–53.3%). Both parameters did not show different outcomes after distinguishing larynx from hypopharynx. LE was indicated in 15 non-responders after ICHT. Five of the 15 non-responders refused the laryngectomy. Two of the five received RT instead and had no evidence of disease 42 months after RT. Late toxicity (dysphagia III, IV LENT SOMA score in laryngectomy-free survivors: after 6 months, 1.8%; 12 months, 11.4%; 18 months, 14.5%; 24 months, 8.1%; 36 months, 16%) and salvage surgery (4 pharyngocutaneous fistulas in 27 operations) were tolerable. In a large portion of patients eligible for LE, the larynx could be preserved with satisfying functional outcome. Good responders after ICHT had also a good general outcome with relatively rare severe late toxicities. Due to a slight increase of relevant late dysphagia, functional outcome regarding swallowing and tracheotomy free breathing should be more focused in future larynx organ preservation trials.


Induction chemo Larynx Hypopharynx cancer Organ preservation Head and neck 


  1. 1.
    Adelstein DJ, Leblanc M (2006) Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24(17):2624–2628CrossRefPubMedGoogle Scholar
  2. 2.
    Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, Eliachar I, Strome M, Van Kirk MA (1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy aline in resectable stage III and IV squamous cell head and neck cancer: preliminary results, chemoradiotherapy versus radiotherapy. Head Neck 19:567–575CrossRefPubMedGoogle Scholar
  3. 3.
    American Society of Clinical Oncology, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O’Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT (2007) American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 25(6):735–736Google Scholar
  4. 4.
    Brasnu DF, Hartl DM (2008) The Laryngologist in organ preservation for laryngeal cancer, letter to the editor. Laryngoscope 118(4):759–760CrossRefPubMedGoogle Scholar
  5. 5.
    Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, Bourhis J, Guerrif S, Garaud P (2006) Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement) 5506Google Scholar
  6. 6.
    Denis F, Garaud P, Bardet E (2003) Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced stage oropharynx carcinoma: comparison of the LENT/SOMA, RTOG/EORTC, and the NCI-CTC scoring sytems. Int J Radiat Oncol Biol Phys 55:93–98CrossRefPubMedGoogle Scholar
  7. 7.
    Dietz A, Nollert J, Eckel H, Volling P, Schroder M, Staar S, Conradt C, Helmke B, Dollner R, Muller RP, Wannenmacher M, Weidauer H, Rudat V (2002) Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study. HNO 50:146–154CrossRefPubMedGoogle Scholar
  8. 8.
    Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B, Weidauer H (1998) Chronic laryngeal edema as a late reaction to radiochemotherapy. HNO 46(8):731–738CrossRefPubMedGoogle Scholar
  9. 9.
    Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098CrossRefPubMedGoogle Scholar
  10. 10.
    Forastiere AA, Trotti A, Pfister DG, Grandis JR (2006) Head and neck cancer: recent advances and new standards of care. J Clin Oncol 24(17):2603–2605CrossRefPubMedGoogle Scholar
  11. 11.
    Hillman RE, Walsh MJ, Wolf GT, Fisher SG, Hong WK (1998) Functional outcomes following treatment for advanced laryngeal cancer. Part I—voice preservation in advanced laryngeal cancer. Part II—laryngectomy rehabilitation: the state of the art in the VA System. Research Speech-Language Pathologists. Department of Veterans Affairs Laryngeal Cancer Study Group. Ann Otol Rhinol Laryngol Suppl 172:1–27PubMedGoogle Scholar
  12. 12.
    Hinni ML, Salassa JR, Grant DG, Pearson BW, Hayden RE, Martin A, Christiansen H, Haughey BH, Nussenbaum B, Steiner W (2007) Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 133(12):1198–1204CrossRefPubMedGoogle Scholar
  13. 13.
    Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A, Robinson RA (2006) Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 116(9):1529–1542CrossRefGoogle Scholar
  14. 14.
    Knecht R, Baghi M, Hambek M, Tesch H, Gstottner W (2003) Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN). Proc Am Soc Clin Oncol 22:501 (abstract 2017)Google Scholar
  15. 15.
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899CrossRefPubMedGoogle Scholar
  16. 16.
    Pfreundner L, Hoppe F, Willner J, Preisler V, Bratengeier K, Hagen R, Helms J, Flentje M (2003) Induction chemotherapy with paclitaxel and cisplatin and CT-based 3D radiotherapy in patients with advanced laryngeal and hypopharyngeal carcinomas—a possibility for organ preservation. Radiother Oncol 68:163–170CrossRefPubMedGoogle Scholar
  17. 17.
    Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949–955CrossRefPubMedGoogle Scholar
  18. 18.
    Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 25;357(17):1705–1715CrossRefGoogle Scholar
  19. 19.
    Rosenthal DI, Lewin JS, Eisbruch A (2006) Dysphagia after radiation therapy or chemoradiation for head and neck cancer. J Clin Oncol 24:2636–2643CrossRefPubMedGoogle Scholar
  20. 20.
    Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH (1995) RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 31(5):1041–1042CrossRefPubMedGoogle Scholar
  21. 21.
    Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M, Eckel HE, Mueller RP (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: Results of a multcentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50:1161–1171CrossRefPubMedGoogle Scholar
  22. 22.
    The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685–1690CrossRefGoogle Scholar
  23. 23.
    Trotti A, Bentzen SM (2004) The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22(1):19–22CrossRefPubMedGoogle Scholar
  24. 24.
    Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N, Taylor J (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24(4):593–598CrossRefPubMedGoogle Scholar
  25. 25.
    Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 25;357(17):1695–1704CrossRefGoogle Scholar
  26. 26.
    Willner J, Baier K, Pfreundner L, Flentje M (1999) Tumor volume and local control in primary radiotherapy of nasopharyngeal carcinoma. Acta Oncol 38:1025–1030CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Andreas Dietz
    • 1
    • 21
    Email author
  • Volker Rudat
    • 2
  • Jens Dreyhaupt
    • 3
  • Maria Pritsch
    • 3
  • Florian Hoppe
    • 4
  • Rudolph Hagen
    • 5
  • Leo Pfreundner
    • 6
  • Ursula Schröder
    • 7
  • Hans Eckel
    • 8
  • Markus Hess
    • 9
  • Michael Schröder
    • 10
  • Petra Schneider
    • 11
  • Bünzel Jens
    • 12
  • Hans P. Zenner
    • 13
  • Jochen A. Werner
    • 14
  • Rita Engenhardt-Cabillic
    • 15
  • Bernhard Vanselow
    • 16
  • Peter Plinkert
    • 17
  • Marcus Niewald
    • 18
  • Thomas Kuhnt
    • 19
  • Wilfried Budach
    • 20
  • Michael Flentje
    • 6
  1. 1.Department of Otolaryngology, Head and Neck SurgeryUniversity of LeipzigLeipzigGermany
  2. 2.Saad Specialist HospitalAl KhobarKingdom of Saudi Arabia
  3. 3.Institute for Medical Biometry and InformaticsUniversity of HeidelbergHeidelbergGermany
  4. 4.Department of Otolaryngology, Head and Neck SurgeryCity Hospital OldenburgOldenburgGermany
  5. 5.Department of Otolaryngology, Head and Neck SurgeryUniversity of WürzburgWürzburgGermany
  6. 6.Department of Radiation OncologyUniversity of WürzburgWürzburgGermany
  7. 7.Department of Otolaryngology, Head and Neck SurgeryUniversity of LübeckLübeckGermany
  8. 8.Department of Otolaryngology, Head and Neck SurgeryHospital KlagenfurtKlagenfurtAustria
  9. 9.Department of Otolaryngology, Head and Neck SurgeryUniversity of HamburgHamburgGermany
  10. 10.Department of Otolaryngology, Head and Neck SurgeryCity Hospital KasselKasselGermany
  11. 11.Department of Radiation OncologyCity Hospital KasselKasselGermany
  12. 12.Department of Otolaryngology, Head and Neck SurgeryCity Hospital NordhausenNordhausenGermany
  13. 13.Department of Otolaryngology, Head and Neck SurgeryUniversity of TübingenTübingenGermany
  14. 14.Department of Otolaryngology, Head and Neck SurgeryUniversity of MarburgMarburgGermany
  15. 15.Department of Radiation OncologyUniversity of MarburgMarburgGermany
  16. 16.Department of Otolaryngology, Head and Neck SurgerySt.VincentiusKarlsruheGermany
  17. 17.Department of Otolaryngology, Head and Neck SurgeryUniversity of HeidelbergHeidelbergGermany
  18. 18.Department of Radiation OncologyUniversity of Homburg/SaarlandHomburg/SaarlandGermany
  19. 19.Department of Radiation OncologyUniversity of HalleHalleGermany
  20. 20.Department of Radiation OncologyUniversity of DüsseldorfDüsseldorfGermany
  21. 21.Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde/Plastische OperationenUniversität LeipzigLeipzigGermany

Personalised recommendations